Glucuronosyltransferase 1A1/UGT1A1 Antibody [Alexa Fluor® 647]

• Applications: WB, IHC, ICC/IF
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Alexa Fluor 647

Glucuronosyltransferase 1A1/UGT1A1 Antibody [Alexa Fluor® 647] Summary

• Immunogen: E. coli-derived recombinant human Glucuronosyltransferase 1A1/UGT1A1
  Leu60-Thr168
  Accession # P22309
• Specificity: Detects human Glucuronosyltransferase 1A1/UGT1A1 in direct ELISAs and Western blots.
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Purity Statement: Antigen Affinity-purified

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Background

UGT1A1 (UDP-glucuronosyltransferase 1-A1; also UDPGT 1-1 and HUG-BR1) is a 52-57 kDa member of the UGT1A subfamily, UGT family of enzymes. UGT1A1 is expressed by the liver, and catalyzes the conjugation of glucuronic acid (GA) from UDPGA to lipophilic acceptors such as (anti-cancer) drugs and bilirubin. Addition of glucuronic acid increases target solubility and facilitates elimination. Mature human UGT1A1 is a 508 amino acid (aa) type I transmembrane ER glycoprotein. It contains a 465 aa luminal domain (aa 26-490) plus a 26 aa cytoplasmic region. The luminal domain is unusual in that aa 157-176 are embedded in the ER membrane. Amino acids 29-444 contain the enzyme active site. The cytoplasmic tail appears to mediate noncovalent homodimerization, and heterodimerization with UGT2B. The signal sequence (aa 1-25) is normally cleaved, but a Lys15Arg mutation blocks insertion into the ER membrane. There are multiple point mutations that impact enzyme activity. One potential splice form is reported that shows a six aa substitution for aa 289-533. Over aa 60-186, human UGT1A1 shares 64% aa identity with mouse UGT1A1.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.